---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-23-000045"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:41:33.938168+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q1 revenue $5.4M (+8% YoY); biologics/drug delivery +24%; reaffirms FY23 guidance $25-27M

## Summary
- Revenue $5.4M (+8% YoY); biologics and drug delivery revenue $2.7M (+24% YoY) drove growth.
- Gross margin fell to 59% from 64% due to higher biologics services costs and overhead.
- Operating expenses $8.9M vs $7.1M, driven by headcount and stock-based compensation increases.
- Cash and short-term investments $31.7M, down from $37.5M; operating cash used $5.7M in quarter.
- Reaffirmed full-year 2023 revenue guidance of $25-27M, implying 22-35% YoY growth.

## SEC filing metadata
- accession: 0001285550-23-000045
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/0001285550-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/clpt-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-23-000045
- JSON: https://secwatch.observer/filing/0001285550-23-000045.json
- Plain text: https://secwatch.observer/filing/0001285550-23-000045.txt

## Key facts
- Earnings Releases
  ClearPoint Neuro, Inc. reported first quarter ended March 31, 2023 results: revenue $5.4 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $5.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2023. First Quarter Highlights • Reported quarterly revenue of $5.4 million, a 8% year-over-year increase; • Increased biologics and drug delivery revenue to $2.7 million, a 24% year-over-year increase; • Announced exclusive multi-year licensing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/0001285550-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.